Cargando…

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)

Detalles Bibliográficos
Autores principales:	Salugina, Svetlana O, Fedorov, Evgeny, Kuzmina, Nina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191477/ http://dx.doi.org/10.1186/1546-0096-12-S1-P267

Ejemplares similares

Cryopyrin-associated periodic syndromes (CAPS): report on two cases (Muckle-Wells syndrome (MWS) and CINCA/NOMID)
por: Salugina, SO, et al.
Publicado: (2011)

PReS-FINAL-2241: Cases of cryopyrin-associated periodic syndromes (CAPS) in one single rheumatologic center of Russia
por: Salugina, SO, et al.
Publicado: (2013)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
por: Bibalo, C, et al.
Publicado: (2011)

A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report
por: Hansmann, Sandra, et al.
Publicado: (2011)

Evidence based recommendations for diagnosis and treatment of cryopyrin-associated periodic syndromes (CAPS)
por: Haar, Nienke Ter, et al.
Publicado: (2014)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome
por: Gorodetskiy, Vadim R., et al.
Publicado: (2018)

Familial case of TRAPS syndrome in Russia
por: Fedorov, Evgeny, et al.
Publicado: (2014)

Late onset of the cryopyrin-associated periodic syndrome (CAPS) associated with low level of somatic mosaicism in six patients
por: Rowczenio, D, et al.
Publicado: (2015)

The RaDiCEA Project: cost of illness (COI) analysis applied to Cryopyrin Associated Periodic Syndromes (CAPS)
por: Della Casa Alberighi, O, et al.
Publicado: (2015)

The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014)

The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients
por: Laskari, K, et al.
Publicado: (2015)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Cryopyrin associated periodic syndromes (CAPS): immunological characterization of knock-in mouse model to exploit novel approaches for the modulation of the NLRP3 inflammasome.
por: Bertoni, A, et al.
Publicado: (2015)

Familial case of Muckle-Wells syndrome in the Russian population: a long way to the diagnosis
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics
por: Kuemmerle-Deschner, J, et al.
Publicado: (2011)

Cost-effectiveness analysis and prevention effects of ultra-orphan drugs for rare diseases: an in silico model applied to Cryopyrin Associated Periodic Syndromes (CAPS)
por: Trieste, L, et al.
Publicado: (2015)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
por: Gillespie, Justin, et al.
Publicado: (2010)

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age
por: Caorsi, Roberta, et al.
Publicado: (2013)

French Amyloidosis CAPS study: AA Amyloidosis complicating cryopyrin-associated periodic syndrome: a study on 14 cases and review of 53 cases from literature
por: Georgin-Lavialle, S, et al.
Publicado: (2015)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

PReS-FINAL-2234: Successful canakunimab treatment in uveitis secondary to cryopyrin-associated periodic syndrome
por: Kasapcopur, O, et al.
Publicado: (2013)

Differences in disease activity in cryopyrin-associated periodic syndrome in mutation-positive and mutation-negative patients
por: Kostik, M, et al.
Publicado: (2015)

Live‐attenuated vaccines in a cryopyrin‐associated periodic syndrome patient receiving canakinumab treatment during infancy
por: Watanabe, Misa, et al.
Publicado: (2017)

Neurology of the Cryopyrin-Associated Periodic Feversyndrome
por: Parker, T, et al.
Publicado: (2015)

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2011)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
por: Saperia, C, et al.
Publicado: (2015)

“Daily life of CAPS patients treated with canakinumab (Ilaris(®)) : data from the French observational study - ENVOL Study”
por: Koné-Paut, I, et al.
Publicado: (2015)

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
por: Church, Leigh D, et al.
Publicado: (2008)

The role of somatic NLRP3 mosaicism and new gene discovery in mutation negative cryopyrin-associated periodic syndrome patients
por: Gomes, Sonia Melo, et al.
Publicado: (2014)

Decreased quality of life and societal impact of cryopyrin-associated periodic syndrome treated with canakinumab: a questionnaire based cohort study
por: Mulders-Manders, Catharina M., et al.
Publicado: (2018)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
por: Walker, Ulrich A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_clf9rcqfr6f9up0t80eld8tqh9